BR112013012175A2 - combinação, coadministração, uso e método - Google Patents

combinação, coadministração, uso e método

Info

Publication number
BR112013012175A2
BR112013012175A2 BR112013012175A BR112013012175A BR112013012175A2 BR 112013012175 A2 BR112013012175 A2 BR 112013012175A2 BR 112013012175 A BR112013012175 A BR 112013012175A BR 112013012175 A BR112013012175 A BR 112013012175A BR 112013012175 A2 BR112013012175 A2 BR 112013012175A2
Authority
BR
Brazil
Prior art keywords
administration
combination
Prior art date
Application number
BR112013012175A
Other languages
English (en)
Inventor
C Ong Christy
Koeppen Hartmut
P Hoeflich Klaus
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112013012175A2 publication Critical patent/BR112013012175A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
BR112013012175A 2010-11-17 2011-11-14 combinação, coadministração, uso e método BR112013012175A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41467110P 2010-11-17 2010-11-17
US201161523062P 2011-08-12 2011-08-12
PCT/EP2011/070008 WO2012065935A1 (en) 2010-11-17 2011-11-14 Methods of treating tumors

Publications (1)

Publication Number Publication Date
BR112013012175A2 true BR112013012175A2 (pt) 2019-09-24

Family

ID=44993549

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013012175A BR112013012175A2 (pt) 2010-11-17 2011-11-14 combinação, coadministração, uso e método

Country Status (9)

Country Link
EP (1) EP2640369A1 (pt)
JP (1) JP2013542965A (pt)
KR (1) KR20130121122A (pt)
CN (1) CN103298461A (pt)
BR (1) BR112013012175A2 (pt)
CA (1) CA2817133A1 (pt)
MX (1) MX2013005507A (pt)
RU (1) RU2013126036A (pt)
WO (1) WO2012065935A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2775601C (en) 2009-09-28 2017-10-03 Qilu Pharmaceutical Co., Ltd 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors
CN104640865B (zh) 2012-09-19 2018-05-11 诺华股份有限公司 作为激酶抑制剂的二氢吡咯烷子基-嘧啶
SG11201507477XA (en) * 2013-03-14 2015-10-29 Genentech Inc Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
US11517539B2 (en) 2016-02-15 2022-12-06 University Of Georgia Research Foundation, Inc. IPA-3-loaded liposomes and methods of use thereof
KR102351270B1 (ko) * 2016-06-16 2022-01-14 하얼빈 젠바오 파마슈티컬 컴퍼니, 리미티드 Akt 억제제인 디히드로피라졸로아제핀계 화합물
US20220218715A1 (en) * 2019-05-22 2022-07-14 Voronoi Co., Ltd. Novel use of pyrrolo-pyridine derivative compound for prevention and/or treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2593428C (en) 2005-01-10 2012-04-17 Pfizer Inc. Pyrrolopyrazoles, potent kinase inhibitors
EP1869052A1 (en) 2005-04-06 2007-12-26 AstraZeneca AB Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
AP2369A (en) 2005-12-21 2012-02-29 Pfizer Prod Inc Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.
CA2691251A1 (en) * 2007-06-19 2008-12-24 Yoshikazu Ohta Preventive/remedy for cancer
US7998688B2 (en) * 2008-03-07 2011-08-16 OSI Pharmaceuticals, LLC Inhibition of EMT induction in tumor cells by anti-cancer agents
US8674095B2 (en) 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions

Also Published As

Publication number Publication date
JP2013542965A (ja) 2013-11-28
WO2012065935A1 (en) 2012-05-24
CA2817133A1 (en) 2012-05-24
CN103298461A (zh) 2013-09-11
RU2013126036A (ru) 2014-12-27
KR20130121122A (ko) 2013-11-05
EP2640369A1 (en) 2013-09-25
MX2013005507A (es) 2013-07-17

Similar Documents

Publication Publication Date Title
BR112012031232A2 (pt) método, dispositivo e uso
SMT201600226B (it) Alcune amminopirimidine, loro composizioni e metodi per il loro uso
BR112012002349A2 (pt) composto,e, uso do mesmo
BR112013007506A2 (pt) piridinonas/pirazinonas - métodos de criação e de uso
BR112013010725A2 (pt) método, e, composição
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BRPI1012861A2 (pt) catalisador, e, uso do catalisador
BR112014031262A2 (pt) composições biocatalisadoras inovadoras e processos para uso.
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BR112012003792A2 (pt) gel tópico, e, uso do gel tópico.
BR112013013584A2 (pt) endoscópio, e, método
BR112013010988A2 (pt) composição fluída e uso
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
BR112013013523A2 (pt) centralizador, método, e, uso de um centralizador
BRPI1007494A2 (pt) composto e uso do mesmo
SMT201700064B (it) Antagonisti di d2, metodi di sintesi e metodi di uso
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
BRPI1006996A2 (pt) composição, método e uso
BR112014009178A2 (pt) métodos, uso, receptor e invenção
BRPI0919794A2 (pt) dispositivo para uso intracorpóreo, e, composto
BR112014009476A2 (pt) refletor, iluminador e uso do iluminador
CO6781486A2 (es) Compuestos y su uso
BRPI1011036A2 (pt) uso
BR112014026873A2 (pt) método cosmético, composição cosmética e uso.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.